ox-i-BYOO-ti-nin 
Contraindicated in:
Use Cautiously in:
CV: chest pain, edema, tachycardia.
Derm: ↓ sweating, transdermal only: application site reactions, hot flushes, pruritus.
EENT: blurred vision, hoarseness.
GI: constipation, dry mouth, nausea, abdominal pain, anorexia, diarrhea, dysphagia.
GU: urinary retention, ↑ thirst.
Metab: hyperthermia.
Neuro: dizziness, drowsiness, agitation, confusion, hallucinations, headache.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
(Generic available)
oxybutynin (Oral): Ditropan
Oxybutynin (Transdermal Gel): Gelnique
Oxybutynin (Transdermal Patch): Oxytrol, Oxytrol for Women
Therapeutic Classification: urinary tract antispasmodics
Pharmacologic Classification: anticholinergics
Absorption: Rapidly absorbed following oral administration, but undergoes extensive first-pass metabolism; extended-release tablets provide extended release. Transdermal absorption occurs by passive diffusion through intact skin and bypasses the first-pass effect.
Distribution: Highly bound (>99%) to plasma proteins. Widely distributed.
Metabolism/Excretion: Extensively metabolized by the liver via the CYP3A4 isoenzyme; one metabolite is pharmacologically active; metabolites are renally excreted with negligible (<0.1%) excretion of unchanged drug.
Half-life: 7–8 hr (oral and patch); 30–64 hr (gel).
(urinary spasmolytic effect)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 30–60 min | 3–6 hr | 6–10 hr (up to 24 hr with XL tablet) |
| TD-patch | within 24 hr | 36 hr | 3–4 days |
NDC Code*